Home > Gastroenterology > Nivolumab plus standard-of-care does not meet primary endpoint for mCRC

Nivolumab plus standard-of-care does not meet primary endpoint for mCRC

Presented By
Dr Heinz-Josef Lenz, USC Norris Comprehensive Cancer Center, CA, USA
Conference
ASCO GI 2022
Trial
Phase 3, CheckMate 9X8
In the phase 2/3 CheckMate 9X8 trial, nivolumab plus standard-of-care did not significantly improve progression-free survival (PFS) compared with standard-of-care alone in the first-line treatment of patients with metastatic colorectal cancer (mCRC). However, the results numerically favoured patients receiving additional nivolumab. Moreover, exploratory analyses revealed that patients with CMS1 and CMS3 molecular subtypes, or CD8 levels ≥2% displayed benefits from nivolumab [1]. “The efficacy of standard therapies in patients with mCRC may be enhanced by the addition of an immunotherapeutic agent,” Dr Heinz-Josef Lenz (USC Norris Comprehensive Cancer Center, CA, USA) explained. The phase 2/3 CheckMate 9X8 trial (NCT03414983) investigated whether nivolumab, a PD-1 inhibitor, may deliver patient benefits when added t...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on